© 1995 American Heart Association, Inc.
Articles |
Apolipoprotein A-II Production Rate Is a Major Factor Regulating the Distribution of Apolipoprotein A-I Among HDL Subclasses LpA-I and LpA-I:A-II in Normolipidemic Humans
From the Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.
Correspondence to Daniel Rader, MD, University of Pennsylvania Medical Center, BRB-1 Rm 409, 422 Curie Blvd, Philadelphia, PA 19104-6069.
Abstract HDLs are heterogeneous in their apolipoprotein composition. Apolipoprotein (apo) A-I and apoA-II are the major proteins found in HDL and form the two major HDL subclasses: those that contain only apoA-I (LpA-I) and those that contain both apoA-I and apoA-II (LpA-I:A-II). Substantial evidence indicates that these two subclasses differ in their in vivo metabolism and effect on atherosclerosis, with LpA-I the more specifically protective subfraction against atherosclerosis. The purpose of this study was to investigate the effect of apoA-I and apoA-II production and catabolism on plasma LpA-I and LpA-I:A-II levels. Fifty normolipidemic subjects (those with HDL cholesterol levels in the top and bottom tenth percentiles were excluded) underwent kinetic studies with radiolabeled apoA-I and apoA-II, and the kinetic parameters of apoA-I and apoA-II were correlated with LpA-I and LpA-I:A-II levels. ApoA-I levels were strongly correlated with apoA-I residence times and less strongly correlated with apoA-I production rates. In contrast, apoA-II levels were correlated only with apoA-II production rates and not with apoA-II residence times. Levels of apoA-I in LpA-I were correlated with apoA-I residence times, whereas levels of apoA-I in LpA-I:A-II were correlated primarily with apoA-II production rates. The fraction of apoA-I in LpA-I was highly inversely correlated with apoA-II production rate (r=-.67, P<.001). In multiple regression analysis, apoA-II production rate was the most significant independent variable determining percent apoA-I in LpA-I among all the kinetic parameters. These results indicate that in normolipidemic individuals (1) apoA-I levels are regulated primarily by apoA-I catabolism and apoA-II levels by apoA-II production; (2) the rate of catabolism of apoA-I is an important factor determining LpA-I levels, while the rate of apoA-II production is the major determinant of the amount of apoA-I in LpA-I:A-II; and (3) the rate of apoA-II production is a major factor determining the distribution of apoA-I between LpA-I and LpA-I:A-II, thereby possibly modulating susceptibility to atherosclerosis in humans.
Key Words: apoA-I • apoA-II • kinetics • radiotracer • HDLs
This article has been cited by other articles:
 |
|
 |
|
  S. Dugue-Pujol, X. Rousset, D. Chateau, D. Pastier, C. Klein, J. Demeurie, C. Cywiner-Golenzer, M. Chabert, P. Verroust, J. Chambaz, et al. Apolipoprotein A-II is catabolized in the kidney as a function of its plasma concentration J. Lipid Res., October 1, 2007; 48(10): 2151 - 2161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rashid, B. W. Patterson, and G. F. Lewis Thematic review series: Patient-Oriented Research. What have we learned about HDL metabolism from kinetics studies in humans? J. Lipid Res., August 1, 2006; 47(8): 1631 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ji, G. F. Watts, A. G. Johnson, D. C. Chan, E. M. M. Ooi, K.-A. Rye, A. P. Serone, and P. H. R. Barrett High-Density Lipoprotein (HDL) Transport in the Metabolic Syndrome: Application of a New Model for HDL Particle Kinetics J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 973 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Okubo, K. Ikewaki, S. Sakai, N. Tada, Y. Kawaguchi, and S. Mochizuki Abnormal HDL Apolipoprotein A-I and A-II Kinetics in Hemodialysis Patients: A Stable Isotope Study J. Am. Soc. Nephrol., April 1, 2004; 15(4): 1008 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sauvaget, V. Chauffeton, S. Dugue-Pujol, A.-D. Kalopissis, I. Guillet-Deniau, F. Foufelle, J. Chambaz, A. Leturque, P. Cardot, and A. Ribeiro In Vitro Transcriptional Induction of the Human Apolipoprotein A-II Gene by Glucose Diabetes, March 1, 2004; 53(3): 672 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F. Watts, P. H. R. Barrett, J. Ji, A. P. Serone, D. C. Chan, K. D. Croft, F. Loehrer, and A. G. Johnson Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome Diabetes, March 1, 2003; 52(3): 803 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Blanco-Vaca, J. C. Escola-Gil, J. M. Martin-Campos, and J. Julve Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein J. Lipid Res., November 1, 2001; 42(11): 1727 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. De Oliveira e Silva, D. Foster, M. McGee Harper, C. E. Seidman, J. D. Smith, J. L. Breslow, and E. A. Brinton Alcohol Consumption Raises HDL Cholesterol Levels by Increasing the Transport Rate of Apolipoproteins A-I and A-II Circulation, November 7, 2000; 102(19): 2347 - 2352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Clay, D. H. Pyle, K.-A. Rye, and P. J. Barter Formation of Spherical, Reconstituted High Density Lipoproteins Containing Both Apolipoproteins A-I and A-II Is Mediated by Lecithin:Cholesterol Acyltransferase J. Biol. Chem., March 17, 2000; 275(12): 9019 - 9025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Durbin and A. Jonas Lipid-free apolipoproteins A-I and A-II promote remodeling of reconstituted high density lipoproteins and alter their reactivity with lecithin:cholesterol acyltransferase J. Lipid Res., December 1, 1999; 40(12): 2293 - 2302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Braschi, T. A-M. Neville, M.-C. Vohl, and D. L. Sparks Apolipoprotein A-I charge and conformation regulate the clearance of reconstituted high density lipoprotein in vivo J. Lipid Res., March 1, 1999; 40(3): 522 - 532. [Abstract] [Full Text]
|
|
|
|
|
|
A. Ribeiro, D. Pastier, D. Kardassis, J. Chambaz, and P. Cardot Cooperative Binding of Upstream Stimulatory Factor and Hepatic Nuclear Factor 4 Drives the Transcription of the Human Apolipoprotein A-II Gene J. Biol. Chem., January 15, 1999; 274(3): 1216 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Escolà-Gil, A. Marzal-Casacuberta, J. Julve-Gil, B. Y. Ishida, J. Ordóñez-Llanos, L. Chan, F. González-Sastre, and F. Blanco-Vaca Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet J. Lipid Res., February 1, 1998; 39(2): 457 - 462. [Abstract] [Full Text]
|
|
|
|
|
|
P. J. Pussinen, M. Jauhiainen, J. Metso, L. E. Pyle, Y. L. Marcel, N. H. Fidge, and C. Ehnholm Binding of phospholipid transfer protein (PLTP) to apolipoproteins A-I and A-II: location of a PLTP binding domain in the amino terminal region of apoA-I J. Lipid Res., January 1, 1998; 39(1): 152 - 161. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Tilly-Kiesi, A. H. Lichtenstein, J. Joven, E. Vilella, M. C. Cheung, W. V. Carrasco, J. M. Ordovas, G. Dolnikowski, and E. J. Schaefer Impact of Gender on the Metabolism of Apolipoprotein A-I in HDL Subclasses LpAI and LpAI:AII in Older Subjects Arterioscler. Thromb. Vasc. Biol., December 1, 1997; 17(12): 3513 - 3518. [Abstract] [Full Text]
|
|
|
|
|
|
M. Tilly-Kiesi, A. H. Lichtenstein, J. M. Ordovas, G. Dolnikowski, R. Malmstrom, M.-R. Taskinen, and E. J. Schaefer Subjects With ApoA-I(Lys107->0) Exhibit Enhanced Fractional Catabolic Rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI With AII) Arterioscler. Thromb. Vasc. Biol., May 1, 1997; 17(5): 873 - 880. [Abstract] [Full Text]
|
|
|
|
|
|
A. Marzal-Casacuberta, F. Blanco-Vaca, B. Y. Ishida, J. Julve-Gil, J. Shen, S. Calvet-Márquez, F. González-Sastre, and L. Chan Functional Lecithin:Cholesterol Acyltransferase Deficiency and High Density Lipoprotein Deficiency in Transgenic Mice Overexpressing Human Apolipoprotein A-II J. Biol. Chem., March 22, 1996; 271(12): 6720 - 6728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Brinton Oral Estrogen Replacement Therapy in Postmenopausal Women Selectively Raises Levels and Production Rates of Lipoprotein A-I and Lowers Hepatic Lipase Activity Without Lowering the Fractional Catabolic Rate Arterioscler. Thromb. Vasc. Biol., March 1, 1996; 16(3): 431 - 440. [Abstract] [Full Text]
|
|